Healthcare regulation firm Frier Levitt has analyzed FDA enforcement steps towards “investigate only” peptide distributors. Their conclusion: the FDA considers an item’s classification based upon its supposed use, not its disclaimers. When Internet sites incorporate dosage guides, reconstitution ins